BIIB vs XYL · P/E 21, rev $9.89B vs P/E 27, rev $4.46B
Biogen Inc (BIIB) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the BIIB and XYL stock pages for the full models.
Not investment advice.